JP2006528229A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528229A5
JP2006528229A5 JP2006530210A JP2006530210A JP2006528229A5 JP 2006528229 A5 JP2006528229 A5 JP 2006528229A5 JP 2006530210 A JP2006530210 A JP 2006530210A JP 2006530210 A JP2006530210 A JP 2006530210A JP 2006528229 A5 JP2006528229 A5 JP 2006528229A5
Authority
JP
Japan
Prior art keywords
methyl
dihydro
pharmaceutically acceptable
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006530210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528229A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/050869 external-priority patent/WO2004103407A2/en
Publication of JP2006528229A publication Critical patent/JP2006528229A/ja
Publication of JP2006528229A5 publication Critical patent/JP2006528229A5/ja
Pending legal-status Critical Current

Links

JP2006530210A 2003-05-22 2004-05-19 Pde4阻害剤及びpde5阻害剤を含有する組成物 Pending JP2006528229A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011609 2003-05-22
PCT/EP2004/050869 WO2004103407A2 (en) 2003-05-22 2004-05-19 Composition comprising a pde4 inhibitor and a pde5 inhibitor

Publications (2)

Publication Number Publication Date
JP2006528229A JP2006528229A (ja) 2006-12-14
JP2006528229A5 true JP2006528229A5 (cg-RX-API-DMAC7.html) 2007-07-05

Family

ID=33462087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530210A Pending JP2006528229A (ja) 2003-05-22 2004-05-19 Pde4阻害剤及びpde5阻害剤を含有する組成物

Country Status (23)

Country Link
US (3) US20060094723A1 (cg-RX-API-DMAC7.html)
EP (1) EP1628682B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528229A (cg-RX-API-DMAC7.html)
KR (1) KR20060012004A (cg-RX-API-DMAC7.html)
CN (1) CN1791429A (cg-RX-API-DMAC7.html)
AU (1) AU2004241749B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0410326A (cg-RX-API-DMAC7.html)
CA (1) CA2525946C (cg-RX-API-DMAC7.html)
CO (1) CO5660275A2 (cg-RX-API-DMAC7.html)
EA (1) EA012279B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP056173A (cg-RX-API-DMAC7.html)
GE (1) GEP20084342B (cg-RX-API-DMAC7.html)
IL (1) IL171306A (cg-RX-API-DMAC7.html)
IS (1) IS8181A (cg-RX-API-DMAC7.html)
MA (1) MA27855A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05012302A (cg-RX-API-DMAC7.html)
NO (1) NO333501B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ544040A (cg-RX-API-DMAC7.html)
RS (1) RS52730B (cg-RX-API-DMAC7.html)
TN (1) TNSN05265A1 (cg-RX-API-DMAC7.html)
UA (1) UA83041C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004103407A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508116B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
WO2005023253A1 (en) 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
JP2007536350A (ja) * 2004-05-10 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺気腫の予防又は治療のためのロフルミラストの使用
CN102600144A (zh) * 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
AU2006237300B2 (en) * 2005-04-19 2011-10-13 Takeda Gmbh Roflumilast for the treatment of pulmonary hypertension
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
PT2359826E (pt) * 2006-07-05 2014-01-20 Takeda Gmbh Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2010013925A2 (en) * 2008-07-31 2010-02-04 Dong-A Pharmaceutical. Co., Ltd. Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
CN103826638B (zh) * 2011-09-09 2015-11-25 Sk化学公司 含有pde5 抑制剂的减少皮肤皱纹的组合物
CN107007597A (zh) * 2012-05-31 2017-08-04 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
US10058545B2 (en) * 2016-08-09 2018-08-28 Cipla Limited Method of treating pulmonary arterial hypertension
CN107648224A (zh) * 2017-10-31 2018-02-02 泰州中国医药城中医药研究院 一种治疗和预防心力衰竭药物及其在制药中的应用
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN108976107B (zh) * 2018-08-23 2021-03-23 南方医科大学 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1996006843A1 (en) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
US6127363A (en) * 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
US6417190B1 (en) * 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
NZ527424A (en) * 2001-02-15 2005-02-25 Altana Pharma Ag Phthalayinone-piperidino-derivatives as PDE4 inhibitors
WO2002096423A2 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient

Similar Documents

Publication Publication Date Title
JP2022184886A5 (cg-RX-API-DMAC7.html)
RU2424242C2 (ru) Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1
CA2529007A1 (en) Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
JP2007526285A5 (cg-RX-API-DMAC7.html)
JP2019535664A5 (cg-RX-API-DMAC7.html)
CA2525946C (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
JP2016538316A5 (cg-RX-API-DMAC7.html)
US8278300B2 (en) Use for PDE5 inhibitors
JP2016537384A5 (cg-RX-API-DMAC7.html)
JP2023549055A5 (cg-RX-API-DMAC7.html)
JP2022500402A5 (cg-RX-API-DMAC7.html)
HRP20150987T1 (hr) UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
JP2006511491A5 (cg-RX-API-DMAC7.html)
JP2011511034A5 (cg-RX-API-DMAC7.html)
US20110028510A1 (en) Compositions, Methods, and Kits for Treating Influenza Viral Infections
EP4618980A1 (en) Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases
RU2007102847A (ru) Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev
RU2004133973A (ru) Новая комбинация
WO1999059584A1 (en) Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
RU2004136276A (ru) Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11
EP1865951A1 (en) Method for preventing cardiovascular diseases
Srinivasulu Cherukupalli et al. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo [4, 3-d] pyrimidine scaffold
TH2101000346A (th) สารประกอบเฮเทอโรไบไซคลิคสำหรับยับยั้งแอคทิวิทีของ shp2
TH2101007398A (th) สารยับยั้งที่มีโมเลกุลขนาดเล็กของไคเนสที่เหนี่ยวนำ NF-kB
RU2021107655A (ru) Соединения триазоло-пиримидина и их применение